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ABSTRACT
Assessment of ERBB2 (HER2) status in breast
carcinomas has become critical in determining response
to the humanised monoclonal antibody trastuzumab. The
current joint College of American Pathologists and the
American Society of Clinical Oncology guidelines for the
evaluation of HER2 status in breast carcinoma involve
testing by immunohistochemistry and ﬂuorescence in situ
hybridisation (FISH). However, neither of these modalities
is without limitations. Novel bright ﬁeld in situ
hybridisation techniques continue to provide viable
alternatives to FISH testing. While these techniques are
not limited to evaluation of the HER2 gene, the extensive
number of studies comparing bright ﬁeld in situ
techniques with other methods of assessing HER2 status
allow a robust evaluation of this approach. Analysis of the
literature demonstrates that, when used to assess HER2
gene status, bright ﬁeld in situ hybridisation demonstrates
excellent concordance with FISH results. The average
percentage agreement in an informal analysis of studies
comparing HER2 ampliﬁcation by chromogenic in situ
hybridisation with FISH was 96% (SD 4%); k coefﬁcients
ranged from 0.76 to 1.0. Although a much smaller
number of studies are available for review, similar levels
of concordance have been reported in studies comparing
HER2 ampliﬁcation by methods employing metallography
(silver in situ hybridisation) with FISH. A summary of the
advancements in bright ﬁeld in situ hybridisation, with
focus on those techniques with clinical applications of
interest to the practicing pathologist, is presented.
INTRODUCTION
Historical perspectives on in situ hybridisation
At the time of Watson and Crick’s published
description of DNA structure in 1953,
1 Tjio and
Levan had yet to publish the ﬁrst reliable determi-
nation of the normal human chromosome comple-
ment.
2 Much discovery was still needed before early
knowledge of DNA technology could be applied to
the ﬁeld of cytogenetics.
3 Although the technique of
DNAeDNA hybridisation had been introduced in
1961,
4 it was not until 1969 that successful
attempts using radiographically labelled DNA and
RNAto identify chromosomal targets of cytological
preparations were made.
56These early studies
relied upon a tritium-labelled RNA probe, derived
from mixtures of Xenopus 28S and 18S RNA, and
alkaline denaturation of extrachromosomal rDNA
from Xenopus oocytes.
5 Hybridised sequences were
detected by autoradiography. Although limited by
the resolution of the radiographic detection method
employed, Gall andPardue were able to demonstrate
that RNA, and soon after DNA, can be hybridised
speciﬁcally to target sequences under conditions
that ‘preserve the morphological integrity of the
nucleus’.
56Furthermore, the ability of this in situ
technology to quantify relative amounts of target
sequence was suggested by the detection of a low
level gene ampliﬁcation in premeiotic oogonia.
5
Additional successes were soon reported in
employing autoradiographic detection of rRNA and
DNA hybrids in tissue sections and in cytological
specimens.
78
Over the years, much improvement has been
made in the processes with which probes are
developed and labeled, including the introduction
of random primer labelling, nick translation reac-
tion and PCR-based labelling.
3 Revolutionary
discoveries were reported in 1982 by two groups
who performed hybridisation experiments with
probes labelled either ﬂuorimetrically or cyto-
chemically, rather than with radioisotopes.
91 0
These ﬂuorescent labels provided many advantages
to the in situ hybridisation technique, including
improvements in the easy and safety of use,
increases in resolution, and the possibilities of
simultaneously identifying multiple targets within
the same nucleus.
11 This new technique, ﬂuores-
cence in situ hybridisation (FISH), could be
accomplished using a probe labelled either directly
or indirectly with a ﬂuorochrome, and the basic
principles of these labelling techniques have been
recently reviewed.
12 Brieﬂy, direct labelling is the
process of incorporating ﬂuorescently labelled
nucleotides into the nucleic acid probe; indirect
labelling often involves complexing the probe with
an intermediary hapten (eg, digoxigenin) that is
subsequently detected with a labelled antibody to
identify the target sequence of interest.
By 1985, another milestone in the in situ
hybridisation technique was achieved when Land-
egent et al demonstrated localisation of the human
thyroglobulin gene to a speciﬁc chromosome band
using a probe constructed from cosmid subclones of
the 39 region of the thyroglobulin gene.
13 By the
turn of the century, further reﬁnement of the FISH
technique lead to routine localisation of DNA
targets as small as 10 kb and the ability to localise
segments as small as 1 kb.
11 Technical advance-
ments through the years have spawned a variety of
FISH technologies,
14 and many of these experi-
mental achievements are considered among the
most signiﬁcant milestones in the ﬁeld of cytoge-
netics and molecular pathology.
3 FISH has been
particularly successful for mapping single-copy and
repetitive DNA sequences using metaphase and
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Reviewinterphase nuclei, for detecting targeted chromosome trans-
locations, and for localising large repeat families to aid in chro-
mosome identiﬁcation and karyotype analysis. The research
application of this technology is vast; clinically, FISH has proved
invaluable in the diagnosis, prognostication and pharmacoge-
nomic assessment of many diseases.
Despite the advantages of FISH, the technique is not without
drawbacks. Often cited limitations to the routine implementa-
tion of conventional FISH include the requirements of a dedi-
cated ﬂuorescence imaging system and well-trained personnel
with speciﬁc expertise. Furthermore, FISH studies provide rela-
tively limited morphological assessment of overall histology,
reduced stability of the ﬂuorescent detection signal(s), and
overall higher cost of testing. These limitations have prompted
new achievements in the arena of in situ hybridisation detec-
tion. The purpose of this review is to summarise the advance-
ments in bright ﬁeld in situ hybridisation in use today with
a focus on those techniques with clinical applications of interest
to the practicing pathologist.
Clinical applications of bright ﬁeld in situ hybridisation: the HER2
story and beyond
The continuous evolution of our understanding of the molecular
pathogenesis of disease is perpetually altering our clinical decision
making and therapeutic strategies. These changes have placed
pressure upon clinical laboratories to provide adequate testing
platforms to provide insight into the status of the disease of an
individual patient. For many neoplastic processes, tissue micro-
scopic morphology is the foundation to a diagnosis being made,
and parafﬁn-embedded tissue provides an abundant source of
archived material for molecular testing. As the need for molecular
testing has increased, multiple techniques have been created or
incorporated into the clinical laboratory to provide these neces-
sary results. The various in situ hybridisation techniques meld
a focused genetic technique upon the histology slide platform.
Nonetheless, the amount of architectural information available
for review depends on the type of in situ hybridisation procedure
used. Bright ﬁeld in situ hybridisation is particularly beneﬁcial in
this regard, as the majority of the morphological detail present on
routine H&E-stained sections is preserved. Although in situ
hybridisation can be used to assess a myriad ofdifferentmolecular
genetic aberrations,
15 investigation of the HER2 gene status in
breast carcinoma has been a major impetus for the development
of bright ﬁeld in situ hybridisation techniques.
As one of the ﬁve leading causes of cancer deaths worldwide,
The World Health Organization recently projected that breast
cancer will cause 630000 deaths in 2015.
16 This disease burden
necessitates efﬁcient use of limited healthcare resources. The
ability to target speciﬁc genetic aberrations that are susceptible
to a speciﬁc therapy is becoming a best clinical practice for
treating a variety of diseases, particularly neoplasia. Discovery of
the role of HER2 in breast cancer, and subsequent discovery of
a viable corresponding gene-speciﬁc therapy, highlights the
central role of a speciﬁc genetic aberration in some breast cancers,
the ability to create therapeutics that target these speciﬁc aber-
rations, and the crucial necessity to identify the molecular
genetic status of an individual’s breast cancer to personalise the
clinical management. The experience with HER2 in breast
carcinoma exempliﬁes the melding of a speciﬁc laboratory test
with a speciﬁc therapy, pharmacogenomics, and the important
role of in situ technology in clinical practice.
HER2 (ERBB2) is a proto-oncogene that encodes for a 185
kDaproteinthatisamemberoftheERBfamilyoftransmembrane
tyrosine kinase receptors. This receptor exists in a dimerisation-
ready conformation, and does not require ligand binding to form
functional dimers. Although it can form homodimers, it rarely
does. Rather, it preferentially forms heterodimers with the
remaining members of its family, particularly HER3.D e p e n d i n g
upon the heterodimer, various signalling pathways are activated.
17
This results in HER2 playing a role in different cellular functions,
including the promotion of cell division and survival, while
inhibiting apoptosis. These various functions reﬂect its potential
toproduce anoncogenic effectfollowing HER2geneampliﬁcation.
In 1987, Slamon et al published the ﬁrst study identifying the
role of HER2 in a subset of breast cancers.
18 The authors
demonstrated that HER2 ampliﬁcation by Southern blotting was
an independent variable linked to inferior overall survival and
progression-free survival in multivariate analysis. During this
same time period, Greene et al provided evidence that monoclonal
antibodies against the p185 product of HER2 inhibited HER2-
transformed cell lines implanted in nude mice.
19 These studies,
among others, laid the foundation for the development of
a targeted therapy in breast cancer: trastuzumab.
Trastuzumab, or Herceptin, is a humanised monoclonal anti-
body against the 185 kDa protein of HER2. Its effect upon HER2-
positive breast cancer is not limited to the immune response
upon antibody binding. Rather, its effects are diverse and include
the inhibition of dimerisation, induction of apoptosis, decreased
cellular proliferation, and the modulation of signal transduction
pathways. In 2001, the ﬁrst phase III clinical trial of trastuzumab
was published by Slamon et al.
20 This prospective study exam-
ined the effect of trastuzumab on overall and progression-free
survival in a cohort of women with metastatic breast cancer. A
signiﬁcant improvement in progression-free survival was
demonstrated when trastuzumab was added to the chemother-
apeutic protocols. Later studies, with a longer follow-up period,
conﬁrmed a signiﬁcant improvement in overall survival when
trastuzumab was added to the treatment of women with
metastatic breast cancer. In 2007, the HERA international
multicentre randomised trial reported on the use of trastuzumab
in patients with HER2-ampliﬁed early stage breast cancers.
21 A2 -
year follow-up of the study showed a signiﬁcant improvement in
overall survival when trastuzumab was used in conjunction with
standard therapeutic regimens. Currently, trastuzumab is used in
the adjuvant setting for treatment of early stage breast cancer as
well as metastatic breast cancer. Although the role of trastu-
zumab as neoadjuvant therapy is still being investigated,
22
preliminary studies have demonstrated a signiﬁcantly better
pathological complete response in patients receiving neoadjuvant
trastuzumab in combination with other agents.
23e25
Throughout these studies, the drug toxicity of trastuzumab
has been a concern, particularly the cardiac side effects.
26 These
ranged from mild left ventricular dysfunction to severe conges-
tive heart failure. The severity of side effects further emphasised
the clinical imperative to use trastuzumab only in the subset of
patients whose clinical beneﬁt would outweigh the risk of
treatment side effects.
The clinical utility of trastuzumab, juxtaposed with the
potential for drug toxicity, mandates the use of this therapy in
the select group of patients who demonstrate HER2 ampliﬁca-
tion. This creates a clinical laboratory imperative to provide
accurate and precise testing when assessing the HER2 status in
breast cancer patients. In 2007, the American Society for Clinical
Oncology and the College of American Pathologists (ASCO/
CAP) published a joint guideline to standardise HER2 testing in
the USA.
27 28 The panel provided testing algorithms and test
interpretation guidelines. The concern of equivocal or false
positive results by immunohistochemistry is illustrated in the
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Reviewinterpretation guidelines. The panel redeﬁned 2+ immunohis-
tochemical staining for the HER2 gene product as equivocal,
rather than positive. This change reﬂects two features previously
identiﬁed of this category of test results. First, a large portion of
cases that stain 2+ fail to show gene ampliﬁcation by FISH.
Considering that FISH has a high concordance with Southern
blotting, it was decided that 2+ scoring was equivocal with
regards to HER2 status rather than positive. Second, up to 15% of
clinical cases assessed using immunohistochemistry (IHC) fall
within the equivocal category. Their recommendation requires
that cases that are equivocal by IHC be retested using a validated
assay for the HER2 gene status. Speciﬁc guidelines for interpre-
tation of bright ﬁeld in situ hybridisation results were also
provided by the panel.
These pressures provide impetus to further develop laboratory
tests to fulﬁl this testing requirement. Although an armamen-
tarium of strategies to detect HER2 status in research and clinical
laboratories exists, including Southern blotting, PCR, IHC and
FISH, the limitations of each of these have been documented.
29
More speciﬁcally, although FISH is a robust test, its complicated
procedure coupled with high technical expertise requirements
precludes its use except in laboratories equipped and staffed to
perform and interpret this highly complex testing. Over the last
decade, the development of bright ﬁeld in situ hybridisation
techniques attempts to address the difﬁculties limiting wide-
spread FISH testing.
Although bright ﬁeld in situ hybridisation has gained much
attention through the need to develop an accurate test of HER2
status that can be performed efﬁciently and cost effectively in
many clinical laboratories, the application of this technology is
not conﬁned to assessment of HER2 status in breast carcinomas.
Several other gene targets have been under investigation, and the
implications of testing for these have been reported.
30e34
Recently, published studies have used chromogenic in situ
hybridisation as a means of assessing platelet-derived growth
factor receptor A in gliomas,
35 determining ampliﬁcation of the
epidermal growth factor receptor (EGFR) gene in anal squamous
lesions,
36 and correlating the EGFR gene copy number with
therapy response in colorectal cancers.
37 Furthermore, the use of
silver-enhanced in situ hybridisation to evaluate EGFR status in
human glioblastomas has demonstrated strong concordance
with FISH and gene expression data.
38 The principles of various
bright ﬁeld technologies in use today, along with their beneﬁts
and limitations, are described below.
A NEW DAWN APPROACHES
Chromogenic in situ hybridisation
The basic principles of in situ hybridisation are straight forward
and can be simpliﬁed as: use of a DNA probe complementary to
a target sequence of interest followed by detection of the bound
probe.
39 Generation of the probe, method of labelling, condition
of hybridisation, and strategy for detection are all areas of nuance
that depend upon the type of in situ hybridisation technique
employed.
40 Chromogenic in situ hybridisation (CISH) was ﬁrst
described by Tanner et al in 2000 as an alternative to FISH
detection of HER2 ampliﬁcation in archival breast tissue.
41 In
that study, parafﬁn-embedded tissue sections were pretreated
and subsequently hybridised with a digoxigenin-labelled DNA
probe. The probe was detected by use of antidigoxigenin ﬂuo-
rescein, followed by antiﬂuorescein peroxidase and diamino-
benzidine. The basic principles of this CISH technique are
outlined in ﬁgure 1.
Although enzymatic DNA in situ hybridisation of CCNDI had
been previously described, the study by Tanner et al was the ﬁrst
to examine the status of the HER2 gene in parafﬁn-embedded
tumour samples using a modiﬁed detection system with superior
sensitivity to the antidigoxigenin plus biotynlated-tyramine
ampliﬁcation, with visualisation using diaminobenzidine and
hydrogen peroxide, already in use.
42 While improvements upon
the use of cosmid, P1, PAC and BAC clone probes for bright ﬁeld
in situ hybridisation had been reported,
43 additional advances
were made in the CISH technique through pretreatment of tissue
sections by heating in a microwave followed by a short period of
enzyme digestion. The detection system used was an anti-
digoxigenin-ﬂuorescein isothiocyanate antibody plus an anti-
ﬂuorescein-isothiocyanate horseradish peroxidase conjugate.
41
This original HER2 CISH procedure involved single-colour
detection of one probe, similar to the US Food and Drug
Administration (FDA) approved FISH testing for HER2 available
at the time. Comparison of CISH detection of HER2 to that of
FISH correlated well in the series of 157 breast cancers examined
(93.6% concordance).
41
Since the study by Tanner et al, additional variations of CISH
technology have been evaluated. In general, the CISH technique
employs either antibodies or other proteins (eg, avidin) conju-
gated to an enzyme (eg, horseradish peroxidase) in order to
produce a chromogenic, rather than a ﬂuorometric, reaction.
Unlike FISH, chromogenic in situ hybridisation performs best
when indirect labelling of the probe is used.
12 Examples of the
staining quality that is achievable through the CISH technique
are demonstrated in ﬁgure 2. Although a large variety of
commercial probes are available for testing by FISH, a relatively
limited number of probes are available for CISH.
12 However,
reliable protocols to generate probes for chromogenic and ﬂuo-
rescence in situ hybridisation have been described.
44
Our informal analysis comparing CISH with FISH for detection
of the HER2 gene in breast cancers demonstrates that the average
percentage agreement in the examined studies comparing HER2
ampliﬁcation by CISH and FISH is 96% (SD¼4%) (table 1).
Although not always performed, k coefﬁcients ranged from 0.76 to
Figure 1 Conceptual schematic of single-colour chromogenic in situ
hybridisation demonstrating bright ﬁeld detection of a digoxigenin-
labelled probe. The probe is recognised by an antidigoxigenin ﬂuorescein
isothiocyanate primary antibody followed by detection with an anti-
ﬂuorescein-isothiocyanate horseradish peroxidase (HRP). After addition
and oxidation of diaminobenzidine, a dark brown signal is deposited at the
target site.
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Review1.0 with the exception of one study.
61 Of the studies reviewed, the
ﬁndings from several larger studies warrant additional attention.
In 2004, Isola et al reported a study of paired CISH/FISH
results from 192 breast cancers.
50 Similar to previously published
studies, the authors demonstrated excellent concordance
between CISH and FISH (93.8%), k coefﬁcient 0.875. After
careful analysis of 12 cases that displayed discordance between
the two testing modalities, it was determined that 7 of the 12
could have been resolved by having chromosome 17 information
when performing the CISH evaluation, and the other ﬁve
discrepant cases were due to histological features that were
difﬁcult to identify in the sampled tumour. The authors
concluded that CISH is an accurate and feasible alternative to the
FDA-approved FISH test (Vysis PathVysion; Abbott Molecular,
Des Plaines, Illinois, USA).
In 2006, two groups independently published studies
comparing HER2 status determined by FISH and CISH.
57 58 The
two studies analysed 200 or more breast cancers. Hanna and
Kwok examined tumour samples by CISH and FISH in three
groups based upon HER2 status, as determined by IHC. Out of
groups with either 0/1+ or 3+ staining by IHC, concordance
between CISH and FISH was 97% and 98% respectively. Only 3
of 119 cases demonstrated discordance by these two methods.
From the group with 2+ staining by IHC methodology, 9 of 135
cases demonstrated discordance between CISH and FISH (93%
concordance). Discordant cases were of tumours displaying very
low or borderline ampliﬁcation with FISH. Scoring of samples
with low-level FISH ampliﬁcation is known to be difﬁcult due in
part to the high level of interobserver variability with these
samples.
59 Overall, the authors conclude that evaluation of HER2
by CISH may be a viable alternative to FISH analysis in the
testing algorithm.
Saez et al examined 200 cases of invasive breast cancer to
compare the status of HER2 as determined by CISH and FISH.
57
The examined breast cancer cases were routinely examined by
IHC, and during a 4-year period 95 cases with 0/1+ staining, 43
cases with 2+ staining, and 62 cases with 3+ staining, were
collected for the study. A tissue macroarray of these cases was
generated, and 174 of the cases were available for evaluation by
CISH and FISH. Overall, a concordance of 94.8% was found
between CISH and FISH. Of discordant cases, only one was
identiﬁed as ampliﬁed by FISH and not by CISH. Eight breast
cancersdemonstratedampliﬁcationbyCISH(twocaseswithlow
level ampliﬁcation), but no ampliﬁcation by the FISH technique.
In 2007, van de Vijver et al published an international valida-
tion ring study involving ﬁve pathology laboratories who
undertook CISH assessment of HER2 in breast cancer cases.
59 A
total of 211 invasive breast carcinomas were analysed by CISH,
and the results compared with data generated by FISH testing.
Of the 76 cases with high levels of HER2 ampliﬁcation (HER2/
CEP17 ratio >4), 96% tested positive for ampliﬁcation by CISH.
A concordance rate of 94% was achieved when testing 100 FISH-
negative cases. However, in cases with low-level HER2 ampliﬁ-
cation by FISH (HER2/CEP17 ratio 2.0e4.0), only a 57%
concordance rate was achieved (20/35 CISH scores indicated
ampliﬁcation). In addition to the difﬁcultly in assessing low
ampliﬁcation cases by FISH,part of this discordance was thought
to be due to assessment of only the HER2 locus by CISH,
without normalisation for the chromosome 17 copy number in
tumour samples. Although these cases pose difﬁculty for evalu-
ation by CISH alone, it was proposed that counting signals from
additional cells and using an additional CISH probe for chro-
mosome 17 on an additional slide would be helpful. Even though
it was estimated that the number of clinical breast cancers that
fall into the categoryofborderline ampliﬁcation ofHER2 by FISH
is 1e3%,
59 practical solutions to the level of discordance in the
Figure 2 Examples of HER2 detection using the chromogenic in situ
hybridisation technique in breast carcinoma. (A) Demonstration of non-
ampliﬁed HER2 producing 1e2 signals per nucleus. Examples of HER2
ampliﬁcation where the peroxidase signal exists as either a cluster of
gene copies (B) or as multiple individual gene copies (C). Original
magniﬁcation 3600. Reproduced from Tanner et al
41 with permission
from the American Society for Investigative Pathology.
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Reviewvan de Vijer study are needed. The overall conclusion of the study
by van de Vijer et al was that CISH and FISH have very high
concordance, and that CISH is a viable alternative to FISH for
assessment of HER2 in breast cancer cases.
The study by van de Vijer et al was not theﬁrst to identify that
assessment and interpretation of HER2 cases with very low level
of ampliﬁcation (6e10 signals per cell) beneﬁt from inclusion of
the chromosome17 probe. Inclusion of the chromosome 17 probe
in such cases had proved to be robust and reproducible between
other laboratories.
64 A correlation of 100% was found between
CISH and FISH in one study in which samples scoring more than
two signals per nucleus were controlled using a chromosome 17
CISH probe on adjacent tissue.
45 Using this approach, breast
cancers with aneusomy or polysomy of chromosome 17 can be
distinguished from genuine low-level HER2 ampliﬁcation;
however, FISH was still deemed useful in some instances.
68 It has
been suggested that all breast carcinomas with a HER2 copy
number of 2e7 by FISH should also be analysed for chromosome
17.
69 A similar algorithmic use of a chromosome 17 probe by
CISH would require less time and resources than evaluating
HER2 and chromosome 17 in a routine fashion on all cases.
Recently, Gong et al published a multicentre study examining
the ability to detect HER2 gene status in breast cancer comparing
conventional scoring criteria with the new ASCO/CAP recom-
mendations.
66 The key difference between the ASCO/CAP
guidelines and USA FDA approved manufacturer scoring criteria
for HER2 ampliﬁcation by CISH (Zymed SPOTLight HER2
CISH; Invitrogen, Camarillo, California, USA) and FISH (Vysis
PathVysion) is that no equivocal category is used in the manu-
facturer’s scoring criteria. The current ASCO/CAP guidelines for
HER2 detection by FISH have criteria for non-ampliﬁed (HER2/
CEP17 ratio <1.8), equivocal (HER2/CEP17 ratio 1.8e2.2), and
ampliﬁed (HER2/CEP17 ratio >2.2). Similarly, the ASCO/CAP
guidelines for non-ampliﬁed, equivocal and ampliﬁed cases
detected by CISH are <4, 4e6, and >6, respectively. The authors
concluded that the concordance between CISH and FISH for
positive and negative cases of HER2 ampliﬁcation was excellent
using the guidelines of the manufacturer and those of ASCO/
CAP. Slightly higher concordance rates and reproducibility were
achieved at the two scoring sites using the ASCO/CAP guide-
lines.
Evaluation of the available published data leads to the
conclusion that bright ﬁeld techniques, such as CISH, have
potential to be used as an alternative to FISH testing in the
assessment of HER2 status in breast cancers. In general, CISH is
thought to offer several advantages over the FISH technique
including: the ability to archive CISH prepared material indeﬁ-
nitely, the use of a conventional bright ﬁeld microscope to
interpret staining, the simultaneous assessment of morphology
and gene copy number in the same slide, and the identiﬁcation of
tumour heterogeneity using low-level magniﬁcation.
12 In addi-
tion, CISH is CE marked and FDA approved. Many of these same
advantages are possible through use of another type of bright
ﬁeld in situ hybridisation based on metallographic, rather than
chromogenic, probe detection.
Metallographic in situ hybridisation
Unlike CISH, enzyme metallographic in situ hybridisation
utilises an enzymatic reaction to facilitate the deposition of
metal directly from solution to identify the target site. In
addition to the advantages offered by chromogenic bright ﬁeld in
situ hybridisation, metallographic in situ hybridisation provides
higher sensitivity and resolution for both ampliﬁed and non-
ampliﬁed genes. An excellent review of metallographic bright
ﬁeld in situ hybridisation modalities was recently published
70;
discussion herein will be focused on describing the principles,
practicalities and relative utility of this technology.
Due to limitations of early Nanogold-silver enhancement
procedures that made them cumbersome for routine use,
a simpliﬁed gold-enhanced Nanogold-streptavidin method,
termed gold-facilitated in situ hybridisation (GOLDFISH) was
developed to assess HER2 gene status (ﬁgure 3).
71 This technique,
initially developed as a simpliﬁed way to qualitatively identify
conﬂuent ampliﬁcation signals in tissue sections rather than
a quantitative assessment of discreet dots, demonstrated much
initial promise.
72 The ﬁrst generation gold-facilitated autome-
tallographic bright ﬁeld in situ hybridisation displayed good
interobserver interpretative reproducibility in an examination of
a series of 66 breast carcinomas
73; however, the need to differ-
entiate cases with chromosome 17 aneusomy or polysomy from
those with low-level HER2 ampliﬁcation necessitated use of
a quantitative interpretation method.
72
It was subsequently discovered that horseradish peroxidase
can be used to selectively deposit metal from solution in the
absence of a particulate nucleating agent such as Nanogold. The
basic principles of this new technology, EnzMet, are presented in
ﬁgure 4A. As commercialised enzyme metallography is known as
silver in situ hybridisation (SISH). This advancement produced
discreet spots of metallic silver deposition, from the enzymatic
action of peroxidase on silver acetate in the presence of hydro-
quinone, at the target site, allowing a superior quantitative
assessment of gene copy number.
72 Results of the staining
achieved by this method are demonstrated in ﬁgure 4B,C. The
EnzMet Gene Pro assay, a form of SISH that incorporates
concomitant protein detection, has demonstrated excellent
interobserver reproducibility,
74 75 and several studies have now
Table 1 Comparison of HER2 status using CISH and FISH
methodologies
Reference
Sample
size
No. of
test sites
Concordance
(%)y
k
Coefﬁcient*
Tanner et al
41 157 1 93.6 0.81
Zhao et al
45 62 1 100.0 NS
Dandachi et al
46 38 1 100.0 NS
Gupta et al
47 31 2 83.9 NS
Park et al
48 188 1 94.1 0.84
Arnould et al
49 75 8 96.0 0.97
Isola et al
50 192 2 93.8 0.88
Hauser-Kronberger et al
51 38 1 100.0 NS
Bhargava et al
52 102 1 100.0 NS
Gong et al
53 80 1 95.0 0.85e0.91
Lin et al
54 25 1 92.0 NS
Li-Ning-T et al
55 32 1 96.9 NS
Loring et al
56 110 1 99.0 NS
Saez et al
57 174 1 94.8 0.86
Hanna and Kwok
58 254 1 95.1 0.91
van de Vijver et al
59 211 5 88.6 NS
Cayre et al
60 55 1 91.5 0.76e0.88
Sinczak-Kuta et al
61 55 1 NS 0.53
Di Palma et al
62 161 1 100.0 NS
Carbone et al
63 89 5 98.9 NS
Di Palma et al
64 28 7 98.5 0.91
Pothos et al
65 88 1 100.0 NS
Gong et al
66 226 2 98.8 0.93e1.0
Pedersen and Rasmussen
67 72 1 98.6 0.97
CISH, chromogenic in situ hybridisation; FISH, ﬂuorescence in situ hybridisation; NS, not
speciﬁed.
*95% conﬁdence level unless otherwise speciﬁed, coefﬁcients rounded to two decimal
places.
yWeighted averages were calculated in some instances.
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Reviewbeen published that compare HER2 gene status in breast
carcinomas as determined by SISH and FISH (table 2).
To date, the published studies examining HER2 gene copy
number by SISH have evaluated relatively small series of usually
less than 100 breast cancers each. In 2007, Dietel et al reviewed
a series of 99 invasive breast carcinomas by automated SISH and
FISH.
76 The results were analysed using the ASCO/CAP guide-
lines. Overall concordance was 96%. Discrepant cases were
usually attributable to the presence of intratumoral heteroge-
neity of HER2 ampliﬁcation. The authors concluded that SISH
was as reliable as FISH in determining HER2 ampliﬁcation.
One year later, Carbone et al published a multicentre study
that examined the staining and interpretative reproducibility of
the HER2 SISH assay (Ventana Medical Systems, Tucson,
Arizona, USA) from 89 breast carcinomas using multiple tech-
niques.
63 The reproducibility and efﬁcacy of HER2 SISH staining
was excellent (median Kw value 0.91). Overall concordance
between positive and negative SISH and FISH results was also
superb (93e100%). However, concordance between SISH and
FISH was lower (50%) for a group of eight cases in which the
HER2/CEP17 ratio was between 1.5 and 3.0. These results
suggest that the low-level or intermediate category of ampliﬁ-
cation poses challenges for the SISH,as well as the CISH,method
of testing. This speciﬁc question has not been systematically
addressed for FISH to our knowledge.
In 2009, Sousha et al published an evaluation of HER2 ampli-
ﬁcation in 53 breast cancers by automated SISH and FISH.
77 In
94% of the cases examined, SISH and FISH results were identical
using scoring criteria provided by the manufacturer. Two of the
breast cancers were negative for HER2 ampliﬁcation by SISH and
positive by FISH. Another breast cancer was scored negative by
FISH and positive for ampliﬁcation by SISH. The authors agreed
with the conclusion reached by Dietel et al in stating that
automated SISH detection of HER2 in excised breast cancers
compares very favourably with FISH analysis.
A recent study examining 230 breast cancers with a rapid
SISH scoring technique determined a very high concordance
(99.6%) with FISH testing.
78 The authors employed a ‘SISH
quick-score’ when evaluating HER2 status by SISH. Similar to
the FDA-approved assessment of HER2 status with a single CISH
probe, the SISH quick-score relies upon the number of stain dots
present in tumour cell nuclei. With dots from an epithelial or
ﬁbroblast cell used as a reference signal, the scorers evaluated
HER2 status as: non-ampliﬁcation, aneusomy, polysomy, and
low-level or high-level ampliﬁcation. The two evaluators in this
study were 100% concordant in their interpretation using the
SISH quick-score technique. In addition to conﬁrming the ability
of automated SISH to accurately assess HER2 status in breast
cancers, the data of the study suggest that the use of SISH quick-
score is of additional utility in that it combines the resolution of
SISH the with straightforward interpretation style of the CISH
scoring method.
In sum, the studies available for review suggest that SISH is
a reliable substitution for FISH in the determination of HER2
status in invasive breast carcinoma. Similar to FISH, SISH allows
enumeration of HER2 and chromosome 17 signals enabling
generation of a HER2/CEP17 ratio. The published ASCO/CAP
guidelines, including the equivocal range of HER2 gene ampliﬁ-
cation (HER2/CEP17 ratio of 1.8e2.2), are also readily applied to
this bright ﬁeld in situ hybridisation. The beneﬁts of SISH
detection of HER2 include: very high sensitivity with high
resolution and signal separation, accurate quantitation of gene
ampliﬁcation, excellent visualisation of tissue morphology, and
adaptability for automation.
70 SISH is currently CE marked but
has not yet been FDA approved. While assessment of HER2 using
currently available commercial technology opens up the beneﬁts
of the CISH and SISH platforms to laboratories not able to
perform FISH, additional advances in bright ﬁeld in situ
hybridisation technologies are currently under development.
Figure 3 (A) Schematic of gold-facilitated in situ hybridisation
(GOLDFISH) assay demonstrating recognition of the biotin-labelled probe
with a biotinylated tyramide followed by strepavidin-Nanogold (Nano-
probes). The Nanogold particulate nucleating agent facilitates auto-
metallographic deposition of gold from a solution of silver acetate in the
presence of hydroquinone at the target site. (B) Example of HER2
detection using the GOLDFISH technique with demonstration of non-
ampliﬁed HER2 in inﬁltrating ductal carcinoma producing 1e2 signals per
nucleus. (C) Example of GOLDFISH technique in a breast carcinoma
containing ampliﬁed HER2 that is demonstrated by multiple large
conﬂuent nuclear signals. Original magniﬁcation 3400. Reprinted from
Powel et al
70 with permission from Elsevier.
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Dual-colour FISH is considered the ‘gold standard’ for in situ
assessment of gene copy number, in part because of the superior
spatial resolution offered by this technique and the FDA approval
status of Vysis PathVysion.
12 However, dual colour FISH has the
same disadvantages as single-colour FISH and the additional
limitation that probes producing more intense signal may lead to
the interpretation of biased ratios favouring the brighter probe.
Despite some limitations, the ability to directly assess both and
multiple targets in the same nucleus simultaneously is highly
desirable. Although studies evaluating multicolour detection
procedures for bright ﬁeld microscopy using chromosome speciﬁc
probes had been reported in the past,
80e82 development of dual-
colour CISH using probes for HER2 and chromosome 17 was
reported more recently using single-colour detection of a digox-
igenin-labelled HER2 probe and a biotin labelled chromosome 17
probe.
83 The results of dual-coloured CISH and FISH in that study
showed high concordance (91%, k coefﬁcient 0.82), and the
contrast provided by the two colours allowed for immediate
distinction between HER2 ampliﬁcation and chromosome 17
aneuploidy.
84 Additional reports of dual-colour CISH for the
assessment of HER2 gene status found excellent concordance
when respectively compared with FISH results (98.6% and
94.6%).
67 85 Additional advancements in bright ﬁeld in situ
hybridisation are aiming to provide assessment of both HER2 and
chromosome 17 through techniques to identify both targets either
Figure 4 (A) Schematic of enzyme metallography demonstrating
detection of the probe with a primary anti-hapten antibody followed by
a horseradish peroxidase (HRP)-labelled secondary antibody. Enzyme-
catalysed deposition of metallic silver from the silver acetate solution, in
the presence of hydroquinone, then occurs at the target site. (B) Example
of HER2 detectionusing theenzymemetallography EnzMet technique with
demonstration of non-ampliﬁed breast cancer; 1e2 signals are present in
eachnucleus.(C) Exampleof breastcarcinomacontainingampliﬁedHER2;
multiple distinct signalsarepresentin eachnucleus. Original magniﬁcation
3400. Reprinted from Powel et al
70 with permission from Elsevier.
Table 2 Comparison of HER2 status using SISH and FISH
methodologies
Reference
Sample
size
No. of test
sites
Concordance
(%)y k coefﬁcient*
Sinczak-Kuta
61 63 1 NS 0.38
Dietel et al
76 99 5 96.0 0.75
Carbone et al
63 89 5 98.9 NS
Shousha et al
77 53 1 94.0 NS
Collins et al
78 230 2 99.6 NS
Bartlett et al
79 45 7 96.0 NS
FISH, ﬂuorescence in situ hybridisation; SISH, silver in situ hybridisation; NS, not speciﬁed.
*95%conﬁdencelevelunlessotherwisespeciﬁed, coefﬁcientsroundedtotwodecimalplaces.
yWeighted averages were calculated in some instances.
Figure 5 Conceptual schematic demonstrating dual detection of HER2
and chromosome 17 by bright ﬁeld double in situ hybridisation. By this
technique, dual detection can be accomplished using individual single
haptens. The two probes are incompatible and two rounds of target DNA
denaturation, hybridisation and stringency washes are carried out
sequentially. DNP, dinitrophenol.
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stainingproduced by such techniques are demonstrated in ﬁgure 6.
Recently, automated bright ﬁeld double in situ hybridisation
(BDISH) applications have been described.
86 In the study by
Nitta et al, high consensus concordance was demonstrated
between FISH and BDISH methods. Future versions of this
approach will use simultaneous hybridisations with dual haptens
allowing dual colour detection (DISH) of HER2 and chromosome
17. Depending on the scoring criteria used (historical versus
ASCO/CAP) and whether FISH equivocal cases were included,
the concordance percentages ranged between 95.7% and 100% (k
coefﬁcients 0.89e1.0). Since publication of that study, the utility
of this technology has become apparent,
87 and it has been
suggested that the BDISH automated technique might be used in
replacement of manualdual-colour FISH methodsin the future.
86
Alternatively, techniques combining IHC and BDISH methods
may become the new preferred method of HER2 assessment.
87
In conclusion, the constant elucidation of the molecular
pathogenesis of disease requires that detailed genetic informa-
tion guide clinical decision making and therapeutic strategies.
This demand has placed pressure upon clinical laboratories to
provide testing platforms capable of accurately assessing
genomic signatures. In situ hybridisation techniques are, and
should continue to be, an important part of the pathologist’s role
in the movement towards personalised medicine.
88 The bright
ﬁeld in situ hybridisation techniques presented offer a glimpse at
where the state of diagnostics and pharmacogenomic testing is
headed in terms of accurately assessing the morphological status
and molecular status of a tumour cell simultaneously.
Figure 6 Examples of HER2 and
chromosome 17 detection in non-
ampliﬁed (A) and ampliﬁed (B) breast
carcinomas using the dual-colour dual-
hapten approach. Single HER2 gene (C)
and chromosome 17 polysomy (D) are
demonstrated using bright ﬁeld double
in situ hybridisation. Magniﬁcation
3100. Reproduced from Nitta et al
86
with author permission.
Take-home messages
< Bright ﬁeld in situ hybridisation is a molecular technique that
enables visualisation of cellular target DNA using chromogenic
(eg, chromogenic in situ hybridisation) or enzyme metallo-
graphic (eg, silver in situ hybridisation) methods of detection
with conventional light microscopy.
< Beneﬁts to bright ﬁeld in situ hybridisation include: the ability
to archive prepared material indeﬁnitely, the use of a conven-
tional bright ﬁeld microscope to interpret staining, the
simultaneous assessment of morphology and gene copy
number on the same slide, and the identiﬁcation of tumour
heterogeneity using low-level magniﬁcation.
< An informal analysis of the literature demonstrates excellent
concordance among published comparisons of bright ﬁeld in
situ hybridisation and ﬂuorescence in situ hybridisation
assessment of ERBB2 (HER2) gene status in breast carcinoma.
< Current American Society for Clinical Oncology and College of
American Pathologists interpretation guidelines for FISH
detection of ERBB2 (HER2) gene status in breast carcinoma
arereadilyapplied tobrightﬁeldinsituhybridisationtechniques.
< Effective advocacy, use and interpretation of bright ﬁeld in situ
hybridisation can be an important part of the role of the
pathologist in the movement towards personalised medicine.
Interactive multiple choice questions
This JCP review has an accompanying set of multiple choice
questions (MCQs). To access the questions, click on BMJ
Learning: Take this module on BMJ Learning from the content
box at the top right and bottom left of the online article. For more
information please go to: http://jcp.bmj.com/education Please
note: the MCQs are hosted on BMJ Learningdthe best available
learning website for medical professionals from the BMJ Group.
If prompted, subscribers must sign into JCP with their journal’s
username and password. All users must also complete a one-
time registration on BMJ Learning and subsequently log in (with
a BMJ Learning username and password) on every visit.
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